Novartis and GSK Shift M&A Paradigm with Trio of Deals
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 5 (Table of Contents)
Published: 14 May-2014
DOI: 10.3833/pdr.v2014.i5.2026 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a series of paradigm-changing deals that will significantly reshape the companies’ businesses, Novartis and GlaxoSmithKline (GSK) have agreed to swap certain assets and combine their consumer healthcare units in order to focus on those business areas in which they are most competitive...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS